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SUMMARY
SETTING—Few studies have shown the operational feasibility, safety, tolerability, or outcomes 
of multi-drug-resistant latent tuberculous infection (MDR LTBI) treatment. After two 
simultaneous multidrug-resistant tuberculosis (MDR-TB) outbreaks in Chuuk, Federated States of 
Micronesia, infected contacts were offered a 12-month fluoroquinolone (FQ) based MDR LTBI 
treatment regimen.
DESIGN—Between January 2009 and February 2012, 119 contacts of MDR-TB patients were 
followed using a prospective observational study design. After MDR-TB disease was excluded, 12 
months of daily FQ-based preventive treatment of MDR LTBI was provided by directly observed 
therapy.
RESULTS—Among the 119 infected contacts, 15 refused, while 104 began treatment for MDR 
LTBI. Of the 104 who initiated treatment, 93 (89%) completed treatment, while 4 contacts 
discontinued due to adverse effects. None of the 104 contacts who undertook MDR LTBI 
treatment of any duration developed MDR-TB disease; however, 3 of 15 contacts who refused and 
15 unidentified contacts developed MDR-TB disease.
CONCLUSION—Providing treatment for MDR LTBI can be accomplished in a resource-limited 
setting, and contributed to preventing MDR-TB disease. The Chuuk TB program implemented 
treatment of MDR LTBI with an 89% completion rate. The MDR LTBI regimens were safe and 
well tolerated, and no TB cases occurred among persons treated for MDR LTBI.
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Multidrug-resistant tuberculosis (MDR-TB), defined as TB caused by Mycobacterium 
tuberculosis resistant to at least isoniazid (INH) and rifampin (RMP), threatens communities 
throughout the world. MDR-TB prevalence is increasing, with some countries reporting over 
20% MDR-TB among new TB cases.1 To compound the situation, only 48% of individuals 
with MDR-TB receive adequate treatment by international standards. Worldwide, MDR-TB 
mortality remains high, as 11–20% of treated individuals and 25–40% of untreated 
individuals die of the disease.2–5
Although MDR-TB strains of M. tuberculosis were thought to be less transmissible,5,6 
person-to-person transmission resulting in primary MDR-TB disease in contacts has been 
well demonstrated.7,8 Rapid identification, isolation, and appropriate treatment of patients 
with infectious MDR-TB is essential to cure disease and interrupt further transmission. 
However, the appropriate management of infected MDR-TB contacts is less clear. INH and 
RMP, the standard treatment for drug-susceptible latent tuberculous infection (LTBI), are 
likely ineffective against MDR-TB strains.
To prevent progression to TB disease, several experts recommend that persons with LTBI 
undergo treatment based on the susceptibility results of the source case.9–11 
Fluoroquinolones (FQs) are highly effective against drug-resistant M. tuberculosis and are 
often recommended in combination with other medications.9 However, some FQ-based 
combination MDR LTBI treatment regimens have been poorly tolerated.11–13 Furthermore, 
animal studies have suggested adverse effects on bone and cartilage development, resulting 
in a reluctance to use FQs in pediatric patients.14 MDR-TB experts have suggested that the 
benefits of using FQs outweigh the risks when treating pediatric MDR-TB patients or 
treating MDR-TB contacts for LTBI (MDR LTBI).15,16 As studies reporting MDR-TB 
outcomes have focused on TB disease,17–19 previous articles have highlighted the need for 
studies to demonstrate tolerability, feasibility, safety and efficacy of treatment for MDR 
LTBI.20
We describe our experience in providing MDR LTBI treatment following two simultaneous 
MDR-TB outbreaks in the Federated States of Micronesia (FSM). Our study followed the 
treatment of contacts with LTBI after exposure to infectious MDR-TB patients. The purpose 
of the study was to describe the tolerability and safety of the FQ-based regimens, to examine 
the operational feasibility of LTBI treatment in a resource-poor setting, and to observe 
whether treatment lowered the risk of progression to TB disease.
METHODS
FSM is an independent country located in the Western Pacific that is affiliated with the 
United States by a Compact of Free Association. Chuuk is the largest of the FSM states, 
with a population of 55 000. In 2007, TB incidence in Chuuk was 127 cases per 100 000 
population, 30-fold higher than the US rate (4.4/ 100 000).21 The first documented MDR-TB 
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case in Chuuk was reported in December 2007. By June 2008, without access to second-line 
anti-tuberculosis medications, a total of five cases of MDR-TB had been diagnosed and four 
had died. In July 2008, an investigation found evidence of two MDR-TB outbreaks with 
ongoing transmission among household contacts.22
From patient and family interviews, the investigation identified 232 household or health care 
facility contacts (Figure 1). Household contacts were defined as persons who had spent at 
least one night in the same household as an infectious MDR-TB patient. Health care facility 
contacts were defined as either having provided direct health care services or having 
performed a medical procedure on a MDR-TB patient. LTBI among these contacts was 
diagnosed using the Mantoux tuberculin skin test (TST) using ≥ 5 mm as cut-off. Excluding 
20 contacts who were subsequently diagnosed with TB disease, 119 MDR-TB contacts had 
evidence of LTBI and were offered treatment with FQ-based regimens.23
All contacts were carefully evaluated using symptom review, clinical examination, and chest 
X-ray (CXR) before initiating treatment. Contacts were offered treatment with one of four 
FQ-based regimens tailored to the contact’s age and the source-case isolate drug 
susceptibility testing (DST) result. The regimens were those recommended by the MDR-TB 
Expert Network (Table 1). Health care workers exposed to multiple MDR-TB patients were 
included in the five-drug resistant group. Treatment for MDR LTBI was given by daily 
directly observed therapy (DOT) for 12 months. In some villages, weekend doses were self-
administered. Monthly compensation (US$5) was provided to contacts who completed 90% 
of expected doses.
This study presents a prospective observational cohort design following MDR-TB contacts 
from January 2009 to February 2012. Study participants provided written informed consent 
for data collection. Demographic information, history of TB exposure, clinical data (weight, 
TB symptom screening, bacille Calmette-Guérin status, comorbidities) and CXR findings 
were abstracted onto data collection forms. For contacts aged ≥18 years, baseline 
comorbidities were assessed by measuring random glucose to detect diabetes mellitus 
(DM),24 serum hepatic aminotransferase levels and rapid testing for human 
immunodeficiency virus (HIV) infection using oral specimens. For contacts aged <18 years, 
parents or guardians were interviewed to determine a history of HIV infection or DM. No 
baseline laboratory tests were performed for contacts aged <18 years.
Community workers recruited from communities affected by the MDR-TB outbreaks 
underwent training in performing DOT and assessing for adverse effects. For each contact, a 
monthly summary of DOT adherence and adverse-effect data were collected by the TB 
program. Contacts were evaluated by a clinician at 3-month intervals, with CXR performed 
at 6, 12, 24, and 36 months after initiation of treatment. If indicated, sputum samples or 
gastric aspirates were collected in the treatment or post-treatment monitoring period.
Treatment completion was defined as taking 80% of doses under DOT (292/365 doses) 
within 15 months.25,26 Treatment interruption was defined as missing medications for >2 
consecutive weeks. Discontinued treatment was defined as >2 months of consecutively 
missed doses. The occurrence of adverse effects was reported as person-months, as 
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individualized adverse effect data were recorded monthly for each of the 12 months. Routine 
blood testing was not required for contacts who did not report adverse effects.
Data were entered into Epi-Info 3.5 (Centers for Disease Control and Prevention, Atlanta, 
GA, USA). Bivariate analyses for categorical variables and t-test for continuous variables 
were performed using SAS 9.2 (Statistical Analysis Software Institute, Cary, NC, USA). 
Unadjusted odds ratios (ORs) were calculated to demonstrate differences in treatment 
outcomes; ORs that excluded the 1.0 null value in their 95% confidence interval (CI) were 
considered statistically significant.
Ethics approval was obtained from the Institutional Review Board (IRB) at the Centers for 
Disease Control and Prevention, Atlanta, GA, USA, before the study was undertaken. The 
FSM Department of Health approved the protocol and deferred IRB approval to CDC.
RESULTS
Of the 119 contacts with MDR LTBI, 104 (87%) initiated treatment and 15 (13%) refused 
treatment or discontinued treatment within 2 weeks. The median age of those who began 
treatment was 24 years (range 1–62) (Table 2). The 15 contacts who refused were older 
(median age 32 years), but were otherwise similar to those who initiated treatment. Of the 
104 contacts who began treatment, none was reported to be HIV-infected.
Because of the known increased risk of progression from infection to TB disease in patients 
with DM, all adults were screened using random glucose levels. Nine of the 61 adult 
contacts reported a history of DM, and the remaining 52 adult contacts had random blood 
glucose levels that were not indicative of DM (<200 mg/dl) at baseline screening. None of 
the children had DM according to medical history.
DOT workers compiled missed doses and adverse effect occurrences in their monthly 
reports for each contact. Over the 12-month treatment regimen, the 104 contacts had the 
opportunity to report adverse effects during 1248 person-months (p-m). The number of 
monthly reports available for abstraction was 1038 (83%). Table 3 shows the outcomes of 
contacts who began treatment for LTBI by regimen and age. Overall, 93 (89%) of the 104 
contacts completed LTBI treatment. Of 26 contacts aged <12 years, 25 (96%) completed 
treatment.
Of the 93 contacts who completed treatment over 1 year, the median number of missed 
doses was 3.5. Five of the 93 patients experienced interruptions (>30 days) in treatment—
one due to pregnancy, and four due to adverse effects. After clinical evaluation, all five were 
able to restart and complete treatment within 15 months. For the four adult contacts who 
interrupted treatment due to adverse effects, substituting levofloxacin (LVX) 500 mg daily 
for moxifloxacin (MFX) 400 mg daily resulted in treatment completion.
Among the 11 contacts (11%) who initiated but did not complete LTBI treatment, five 
contacts on MFX-based regimens discontinued for personal reasons, such as travel for 
extended periods of time and emigration. Another two women discontinued treatment after 
becoming pregnant, and declined to reinitiate. The remaining four contacts discontinued due 
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to adverse effects. Three health care workers on MFX monotherapy discontinued treatment, 
two due to nausea or other gastrointestinal disturbances, and one with muscle and joint pain. 
The fourth discontinuation occurred in an 8-year-old child after symptoms of hepatitis were 
noted; serum hepatic aminotransferase levels were elevated. Acute hepatitis A was 
confirmed by serologic testing, but the patient did not resume LTBI treatment after the 
hepatitis resolved.
No serious adverse events, defined as hospitalization or irreversible morbidity, were 
attributed to the 12-month FQ-based regimens in either the adult or pediatric contacts. Fifty-
six (53%) contacts reported at least one adverse effect during MDR LTBI treatment. Only 
16 contacts (15%) reported adverse effects more than three times during the 12-month 
treatment period. Overall, adverse effects were reported during 15% (159/1038) of p-m.
Table 4 shows the frequency of each reported adverse effect. Nausea was the most common, 
reported by 35 contacts during 112 p-m. In addition, dizziness/headache, fatigue and muscle/
joint pain (72, 22, and 21 p-m, respectively) were reported. These adverse effects were 
primarily reported by contacts taking FQ monotherapy (Table 5). Excluding children aged 
<12 years (none of whom were on MFX-based regimens), the odds of reporting any adverse 
effects over the course of treatment were 3.8 times higher (95%CI 1.2–9.2) among contacts 
on MFX monotherapy compared to adults taking other regimens. Among adults only, the 
odds of reporting adverse effects at any point during the 12-month regimen were lower for 
those taking MFX and ethambutol (EMB) compared with contacts taking other regimens 
(OR 0.3, 95%CI 0.1–0.8). Completion rates for both groups were the same (83% vs. 88%, 
OR 1.9, 95%CI 0.5–7.7). When compared with other adult contacts, the odds of reporting 
adverse effects were significantly higher among health care workers (OR 5.5, 95%CI 1.8–
17).
After 36 months of follow-up, none of the 104 contacts who completed MDR LTBI 
treatment developed TB disease. Among the 11 contacts who discontinued MDR LTBI 
treatment, none had progressed to TB disease at 36 months follow-up. Six of these contacts 
took their medications for more than 6 months.
Among the 15 contacts who refused LTBI treatment, three (20%) developed MDR-TB 
disease (Figure 1). Fifteen contacts were diagnosed with MDR-TB disease before treatment 
for LTBI could be offered. A final 13 persons not initially identified as contacts or lost to 
follow-up were diagnosed with MDR-TB disease, resulting in a total of 31 additional 
patients since the initial July 2008 investigation (Figure 2).
DISCUSSION
The experience of treating MDR LTBI in Chuuk adds important information to the sparse 
data on strategies to manage contacts exposed to patients with infectious MDR-TB. 
Management of MDR-TB contacts is challenging in any setting, but resource-poor settings 
must overcome even more challenges, as they often lack reliable diagnostic tools, laboratory 
services, and adequate facilities to provide treatment and expert consultation in the 
management of complicated patients.10,12 Despite substantial infrastructure challenges,27 
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the Chuuk State TB Program has demonstrated that treatment of contacts of patients with 
MDR-TB is feasible.
Despite several statistically significant differences in reported adverse events between 
various regimens, the observed overall completion rate was excellent. Distinctions in 
tolerability may be intrinsic to various regimens, but more likely differ due to patient 
selection (pediatric vs. adult), variability in DOT worker reporting, and variations in cultural 
attributes among families exposed to MDR-TB.
Numerous factors contributed to the high rate of treatment completion in Chuuk. DOT 
workers were recruited from the affected communities and several trusted clinicians led 
community education efforts among community leaders, patients, and families.27 These 
outreach activities established confidence in the TB program and increased the acceptability 
of recommendations for treatment of MDR LTBI. Finally, compensation ($5/month) was 
provided to each contact who completed ≥90% of treatment, which possibly contributed to 
high rates of adherence with treatment.
With careful monitoring, treatment of MDR LTBI was safe and well tolerated. DOT workers 
were trained to recognize medication adverse effects during their daily interactions with 
patients. After 3 years of clinical follow-up, there was no evidence of serious adverse events 
from the various 12-month FQ-based regimens used to treat MDR LTBI.
Our prospective observational study design was intended to describe operational feasibility, 
tolerability, and treatment outcomes rather than efficacy. The study design did not allow a 
definitive statement to be made regarding efficacy for preventing progression to TB disease. 
However, after 3 years of monitoring, none of the contacts who completed MDR LTBI 
treatment regimens developed MDR-TB disease. Furthermore, the finding of 31 additional 
patients with MDR-TB disease among contacts who did not take treatment suggests an 
important protective benefit of treating MDR LTBI.
In a survey of 35 countries with >2% incident MDR-TB, only 11 had written policies on 
how to manage MDR-TB contacts and only three made an effort to treat contacts. The most 
commonly cited reason for not having policies was lack of data or guidance.28 
Unfortunately, lack of data on MDR-TB disease transmission has led to continued 
skepticism about the need to treat MDR-TB contacts.20 Measurement of the efficacy of 
MDR LTBI treatment is needed and should be a priority for future research.
This study presents several limitations. The most important limitation was that the 
observational design did not allow definitive conclusions to be drawn regarding efficacy. 
Second, as four of five initial MDR-TB patients died, contact investigations were conducted 
through proxy interviews.22 Despite concerted efforts to find all possible contacts, 13 
patients with significant exposure to infectious MDR-TB cases were not identified in the 
initial contact investigations, and later developed MDR-TB disease without being offered 
MDR LTBI treatment. It is likely that additional unidentified contacts did not develop 
MDR-TB disease despite not receiving MDR LTBI treatment. A proper estimation of 
efficacy would require knowing the total number of individuals within the Chuukese 
community who were exposed to, but did not develop, MDR-TB disease.
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With aggressive case finding, effective isolation, and treatment of patients hospitalized with 
infectious MDR-TB,27 there was little risk of MDR-TB reinfection among contacts in 
Chuuk. Some of the apparent reported ineffectiveness of LTBI regimens in previous studies 
may be due to high rates of MDR-TB reinfection in high-burden settings.28,29
MDR-TB will continue to be a substantial public health problem, even with excellent DOT, 
uninterrupted supplies of second-line medications, quality laboratory facilities, and public 
health support. When new MDR-TB cases arise, the highest priority must be the rapid 
identification, isolation, and appropriate treatment of patients with infectious MDR-TB.30 
However, after this priority has been addressed, the identification and treatment of infected 
contacts represent an important opportunity for preventing additional MDR-TB within 
communities.
The effort to treat MDR LTBI in Chuuk has proved feasible for the local TB program, 
tolerable and safe for contacts, and potentially life-saving for the broader community. The 
described success of this program may serve as guidance for other programs implementing 
MDR LTBI treatment activities, and may inform future guidelines and policies for the 
treatment of contacts of MDR-TB patients.
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Flow diagram of screening and results of investigation, Chuuk, Federated States of 
Micronesia, 2009–2012. MDR-TB = multidrug-resistant TB; TB = tuberculosis; TST = 
tuberculin skin test: LTBI = latent tuberculous infection.
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MDR-TB outbreak cases (n =36), Chuuk, Federated States of Micronesia, 2009–2012. 
MDR-TB = multidrug-resistant tuberculosis.
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Table 1
Treatment regimens for MDR LTBI, Chuuk, Federated States of Micronesia, 2009–2012*
Source patient isolate MDR LTBI treatment regimen
M. tuberculosis resistant to INH, RMP and 
ETH
Adults aged >12 years: MFX 400 mg by mouth daily and EMB 15 mg/kg by mouth daily for 12 
months
Children aged ≤12 years: LVX 20 mg/kg by mouth daily and EMB 15 mg/kg by mouth daily for 
12 months
M. tuberculosis resistant to INH, RMP, 
PZA, EMB and SM
Adults aged >12 years: MFX 400 mg by mouth daily for 12 months
Children aged ≤12 years: LVX 20 mg/kg by mouth daily and ETH 20 mg/kg by mouth daily for 
12 months
*
Regimens were recommended by the MDR-TB Expert Network, a group of US national TB experts who convene every 2 months to offer expert 
opinion on the treatment and management of challenging drug-resistant cases.
MDR=multidrug-resistant; LTBI=latent tuberculous infection; INH=isoniazid; RMP=rifampin; ETH=ethionamide; MFX=moxifloxacin; 
EMB=ethambutol; LVX= levofloxacin; PZA = pyrazinamide; SM = streptomycin.
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Table 2
Demographics and clinical characteristics of infected contacts who initiated treatment for LTBI, by source 
MDR-TB patient, Chuuk, Federated States of Micronesia, 2009–2012
Demographic characteristic
Source MDR-TB case
Total (n = 104)
n (%)
Resistant to five drugs (n = 63)
n (%)
Resistant to three drugs (n = 41)
n (%)
Age, years
 <5 6 (6) 4 (6) 2 (5)
 5–11 20 (19) 10 (16) 10 (24)
 12–17 17 (16) 6 (9) 11 (27)
 18–25 17 (16) 10 (16) 7 (17)
 26–40 14 (14) 9 (15) 5 (12)
 41–55 17 (16) 14 (22) 3 (7)
 >55 13 (12) 10 (16) 3 (7)
Sex
 Male 48 (47) 28 (44) 20 (49)
 Female 56 (53) 35 (56) 21 (51)
HIV infection*
 Adults tested 61 (55) 29 (47) 15 (37)
 Pediatric (assessed by patient history) 43 (45) 34 (53) 26 (63)
Diabetes mellitus†
 Adults testing positive 9 (9) 7 (11) 2 (5)
*
No individuals tested positive for HIV.
†
Diabetes mellitus screening using random glucose. Values ≥200 mg/dl indicated diabetes mellitus.26
LTBI =latent tuberculous infection; MDR-TB =multidrug-resistant tuberculosis; HIV =human immunodeficiency virus.
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Table 3
Treatment completion rate for MDR-TB contacts by age and regimen, Chuuk, Federated States of Micronesia, 
2009–2012
Patients who started treatment
n
Patients who completed treatment
n (%)
Age, years
 <5 6 6 (100)
 5–11 20 19 (95)
 12–17 17 17 (100)
 18–25 17 14 (82)
 26–40 14 11 (73)
 41–55 17 15 (88)
 >55 13 11 (85)
 Total 104 93 (89)
Treatment regimen
 MFX only 46 36 (83)
 MFX + EMB 24 21 (88)
 LVX only* 5 5 (100)
 LVX + EMB 17 16 (94)
 LVX + ETH 12 12 (100)
 Total 104 93 (89)
*
Four patients who began treatment with MFX alone received <6 months of MFX before completing the remainder of treatment with LVX only. 
These four patients are included in the LVX only group.
MDR-TB = multidrug-resistant tuberculosis; MFX = moxifloxacin; EMB = ethambutol; LVX = levofloxacin; ETH = ethionamide.
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Table 4
Adverse effects reported by contacts during MDR LTBI treatment, Chuuk, Federated States of Micronesia, 
2009–2012
Adverse effect
Adverse effects, number of contacts (n = 104)*
n (%)
Adverse effects, person-months (n = 1038)†
n (%)
Nausea 35 (33) 112 (10.8)
Dizziness/headache 26 (25) 72 (6.9)
Fatigue 16 (15) 22 (2.1)
Muscle and joint pain 10 (9) 21 (2.0)
Abdominal pain 9 (8) 10 (1.0)
Jaundice 1 (1)‡ 1 (0.1)
*
This table includes all contacts who initiated treatment, including those who discontinued treatment.
†
Contacts could report more than one adverse effect each month.
‡
Laboratory-confirmed concomitant acute hepatitis A infection.
MDR = multidrug-resistant; LTBI = latent tuberculous infection.
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